BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36178086)

  • 1. PBRM1 presents a potential prognostic marker and therapeutic target in duodenal papillary carcinoma.
    He X; Xu J; Niu N; Xu G; Zhu H; Liu Z; Mou Y; Qian Z; Wang H; Hu J; Ma T; Ma J; Tao H
    Clin Transl Med; 2022 Oct; 12(10):e1062. PubMed ID: 36178086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBRM1 loss is a late event during the development of cholangiocarcinoma.
    Luchini C; Robertson SA; Hong SM; Felsenstein M; Anders RA; Pea A; Nottegar A; Veronese N; He J; Weiss MJ; Capelli P; Scarpa A; Argani P; Kapur P; Wood LD
    Histopathology; 2017 Sep; 71(3):375-382. PubMed ID: 28394406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.
    Zhou Z; Huang D; Yang S; Liang J; Wang X; Rao Q
    Pathol Oncol Res; 2022; 28():1610479. PubMed ID: 35928964
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma.
    Kim JY; Lee SH; Moon KC; Kwak C; Kim HH; Keam B; Kim TM; Heo DS
    J Urol; 2015 Oct; 194(4):1112-9. PubMed ID: 25997916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.
    Mo D; Li C; Liang J; Shi Q; Su N; Luo S; Zeng T; Li X
    Int J Clin Exp Pathol; 2015; 8(8):9307-13. PubMed ID: 26464681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
    Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBRM1 bromodomains variably influence nucleosome interactions and cellular function.
    Slaughter MJ; Shanle EK; McFadden AW; Hollis ES; Suttle LE; Strahl BD; Davis IJ
    J Biol Chem; 2018 Aug; 293(35):13592-13603. PubMed ID: 29986887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid-inducible gene-I-like receptor signalling and is a potential prognostic biomarker for colon cancer.
    Shu XS; Zhao Y; Sun Y; Zhong L; Cheng Y; Zhang Y; Ning K; Tao Q; Wang Y; Ying Y
    J Pathol; 2018 Jan; 244(1):36-48. PubMed ID: 28940253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual Bromodomains of Polybromo-1 Contribute to Chromatin Association and Tumor Suppression in Clear Cell Renal Carcinoma.
    Porter EG; Dykhuizen EC
    J Biol Chem; 2017 Feb; 292(7):2601-2610. PubMed ID: 28053089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma.
    Wang Z; Peng S; Guo L; Xie H; Wang A; Shang Z; Niu Y
    Clin Chim Acta; 2018 Nov; 486():9-17. PubMed ID: 30006290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma.
    Nam SJ; Lee C; Park JH; Moon KC
    Urol Oncol; 2015 Aug; 33(8):340.e9-16. PubMed ID: 26003625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
    Boorjian S
    Urol Oncol; 2014 Aug; 32(6):934-5. PubMed ID: 25087671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
    Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
    Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genetic and epigenetic analysis of cancer-related genes in non-ampullary duodenal adenomas and intramucosal adenocarcinomas.
    Ota R; Sawada T; Tsuyama S; Sasaki Y; Suzuki H; Kaizaki Y; Hasatani K; Yamamoto E; Nakanishi H; Inagaki S; Tsuji S; Yoshida N; Doyama H; Minato H; Nakamura K; Kasashima S; Kubota E; Kataoka H; Tokino T; Yao T; Minamoto T
    J Pathol; 2020 Nov; 252(3):330-342. PubMed ID: 32770675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma.
    da Costa WH; Rezende M; Carneiro FC; Rocha RM; da Cunha IW; Carraro DM; Guimaraes GC; de Cassio Zequi S
    BJU Int; 2014 May; 113(5b):E157-63. PubMed ID: 24053427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.